Non-mercaptalbumin as a potential biomarker of oxidative stress in Parkinson’s and PARK2 disease
Objective: To elucidate the oxidized albumin ratio, which is the redox ratio of human non-mercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in parkinsonism.…Maladaptive use of LD/CD tablets as painkillers causing Dopamine Dysregulation Syndrome in 4 patients of Advanced Parkinson’s Disease
Objective: To study four cases of maladaptive use of levodopa/carbidopa (LD/CD) as painkillers causing Dopamine dysregulation syndrome (DDS) in Parkinson’s disease (PD) patient in a…Frequency of Impulse Control Disorders and Other Related Behaviors in People with Parkinson’s Disease
Objective: To identify the frequency of impulse control disorders (ICDs) and other related behaviors (i.e. punding, hobbyism, walkabout and dopamine dysregulation syndrome) in people with…Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease
Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…Effects of Rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) Emotional Well-being Domain in Patients with Parkinson’s Disease (PD): A Post-Hoc Analysis of Clinical Trials in Japan
Objective: To evaluate the direct and indirect effects of rasagiline on emotional well-being domain of the PDQ-39 in patients with PD by a post-hoc analysis…Clinical Implication of Stimulus Induced Dyskinesia in Pallidal Deep Brain Stimulation for Advanced Parkinson’s Disease
Objective: To investigate the influence of stimulus induced dyskinesia (SID) on the therapeutic outcome of globus pallidus internus (GPi) deep brain stimulation (DBS) for the…PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…Researches on the correlation between wearable device data and UPDRS scores in patients with Parkinson’s disease
Objective: To collect spatiotemporal parameter information of motor symptoms in patients with Parkinson's disease (PD) using wearable device, and analyze its correlation with the Unified…Randomized, placebo-controlled study investigating the safety, pharmacokinetics and efficacy of inhaled apomorphine in Parkinson’s disease patients
Objective: To evaluate the safety, pharmacokinetics (PK) and efficacy of single-dose apomorphine inhalation in PD patients. Background: Apomorphine is a dopamine agonist, approved for treating…Refining Knowledge on the Treatment of Pisa Syndrome with Botulinum Toxin
Objective: To analyze the efficacy of botulinum toxin (BoNT) in cases of pisa syndrome (PS) associated with Parkinson's disease (PD) targeting paraspinal muscles ipsilateral to…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 149
- Next Page »